Renal Impairment Clinical Trials

11 recruiting

Renal Impairment Trials at a Glance

10 actively recruiting trials for renal impairment are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 1 with 7 trials, with the heaviest enrollment activity in Orlando, Tampa, and Gaia. Lead sponsors running renal impairment studies include Atea Pharmaceuticals, Inc., Barts & The London NHS Trust, and AstraZeneca.

Browse renal impairment trials by phase

Treatments under study

About Renal Impairment Clinical Trials

Looking for clinical trials for Renal Impairment? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Renal Impairment trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Renal Impairment clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

Healthy Volunteer StudyRenal ImpairmentHepatic Impairment
Atea Pharmaceuticals, Inc.28 enrolled2 locationsNCT06911320
Recruiting
Phase 1

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function

HealthyRenal Impairment
Pfizer28 enrolled4 locationsNCT07315360
Recruiting
Phase 1

Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)

Renal Impairment
AstraZeneca50 enrolled2 locationsNCT07154901
Recruiting
Phase 1

Effect of Renal Impairment on Enpatoran Pharmacokinetics

Renal Impairment
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany40 enrolled1 locationNCT06589713
Recruiting
Phase 1

Clofutriben Pharmacokinetics in Patients With Impaired Renal Function

Moderate Renal Impairment
Sparrow Pharmaceuticals16 enrolled1 locationNCT07227922
Recruiting
Phase 1

A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls

Renal Impairment
Shionogi40 enrolled4 locationsNCT07217886
Recruiting
Phase 1

Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants

Renal Impairment
Noucor Health S.A.48 enrolled7 locationsNCT06708520
Recruiting

Development of a Biomarker Panel for the Earlier Prediction of Acute Kidney Injury in Patients With Diabetes

Diabetes MellitusRenal Impairment
Barts & The London NHS Trust250 enrolled1 locationNCT00948116
Recruiting
Phase 2

A Phase II trial of bortezomib and dexamethasone in renally-impaired patients with untreated multiple myeloma.

Untreated Multiple Myeloma patients with renal impairment.
Prof. Andrew Spencer28 enrolled1 locationACTRN12611000605998
Recruiting
Phase 3

Preoperative intranenous N-Acetylcysteine for the prevention of renal failure in patients with renal impairment undergoing cardiac surgery

Renal Impairment in cardiac surgery
Prince of Wales Hospital200 enrolled1 locationACTRN12606000088549